A Multi-center, Open Label, Uncontrolled, Phase IIA Clinical Trial Evaluating the Safety and Efficacy of NOX A12 in Combination With a Background Therapy of Bortezomib and Dexamethasone (VD) in Previously Treated Patients With Multiple Myeloma (MM).

Trial Profile

A Multi-center, Open Label, Uncontrolled, Phase IIA Clinical Trial Evaluating the Safety and Efficacy of NOX A12 in Combination With a Background Therapy of Bortezomib and Dexamethasone (VD) in Previously Treated Patients With Multiple Myeloma (MM).

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Apr 2016

At a glance

  • Drugs Olaptesed pegol (Primary) ; Bortezomib; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors NOXXON Pharma AG
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Apr 2015 The on-treatment phase has been completed, according to a NOXXON Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top